Literature DB >> 7615808

Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA.

I Teitelbaum1, S McGuinness.   

Abstract

Studies were performed to determine the mechanism underlying deficient arginine vasopressin (AVP)-stimulated adenylyl cyclase activity in chronic renal failure (CRF). As compared to control, principal cells cultured from the inner medullary collecting tubule of rats previously made uremic by 5/6 nephrectomy fail to accumulate cAMP when stimulated with AVP. CRF cells do respond normally to forskolin or cholera toxin and the defect in AVP responsiveness is not prevented by treatment with pertussis toxin, by cyclooxygenase inhibition, or by inhibition or down-regulation of protein kinase C. In contrast to their lack of responsiveness to AVP, CRF cells respond normally to other agonists of adenylyl cyclase such as isoproterenol or prostaglandin E2. Plasma membranes prepared from the inner medullae of CRF rats exhibit a marked decrease in apparent AVP receptor number but no change in the apparent number of beta adrenergic receptors. Reverse transcriptase PCR of total RNA from the inner medullae of CRF animals reveals virtual absence of V2 receptor mRNA; mRNA for alpha s is present in normal abundance. These studies indicate that AVP resistance in CRF is due, at least in part, to selective down-regulation of the V2 receptor as a consequence of decreased V2 receptor mRNA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615808      PMCID: PMC185210          DOI: 10.1172/JCI118044

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Observations on the concentrating and diluting mechanisms of the diseased kidney.

Authors:  N S BRICKER; R R DEWEY; H LUBOWITZ; J STOKES; T KIRKENSGAARD
Journal:  J Clin Invest       Date:  1959-03       Impact factor: 14.808

Review 2.  Memory B and T cells.

Authors:  E S Vitetta; M T Berton; C Burger; M Kepron; W T Lee; X M Yin
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Functional profile of the isolated uremic nephron. Impaired water permeability and adenylate cyclase responsiveness of the cortical collecting tubule to vasopressin.

Authors:  L G Fine; D Schlondorff; W Trizna; R M Gilbert; N S Bricker
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Vasopressin-resistant hyposthenuria in advanced chronic renal disease.

Authors:  R L Tannen; E M Regal; M J Dunn; R W Schrier
Journal:  N Engl J Med       Date:  1969-05-22       Impact factor: 91.245

7.  A molecular map of G protein alpha chains in microdissected rat nephron segments.

Authors:  S I Senkfor; G L Johnson; T Berl
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney.

Authors:  R J Anderson; T Berl; K D McDonald; R W Schrier
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

9.  Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction.

Authors:  Y Terada; K Tomita; H Nonoguchi; T Yang; F Marumo
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Alterations in renal endothelin-1 production in the spontaneously hypertensive rat.

Authors:  A K Hughes; R C Cline; D E Kohan
Journal:  Hypertension       Date:  1992-11       Impact factor: 10.190

View more
  12 in total

1.  Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.

Authors:  Takahiro Masuda; Ken Ohara; Izumi Nagayama; Ryo Matsuoka; Takuya Murakami; Saki Nakagawa; Kentanro Oka; Maki Asakura; Yusuke Igarashi; Yukimura Fukaya; Yasuharu Miyazawa; Akito Maeshima; Tetsu Akimoto; Osamu Saito; Daisuke Nagata
Journal:  Int Urol Nephrol       Date:  2019-06-03       Impact factor: 2.370

2.  Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.

Authors:  Wiebke Fenske; Christoph Wanner; Bruno Allolio; Christiane Drechsler; Katja Blouin; Jürgen Lilienthal; Vera Krane
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

3.  Angiotensin II AT1 receptor blockade changes expression of renal sodium transporters in rats with chronic renal failure.

Authors:  Eun-Jung Kim; Yong-Wuk Jung; Tae-Hwan Kwon
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

Review 4.  Dysnatremias in patients with kidney disease.

Authors:  Sara Combs; Tomas Berl
Journal:  Am J Kidney Dis       Date:  2013-11-14       Impact factor: 8.860

Review 5.  Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.

Authors:  Hanne B Moeller; Søren Rittig; Robert A Fenton
Journal:  Endocr Rev       Date:  2013-01-29       Impact factor: 19.871

Review 6.  Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.

Authors:  Serena Milano; Monica Carmosino; Andrea Gerbino; Maria Svelto; Giuseppe Procino
Journal:  Int J Mol Sci       Date:  2017-11-10       Impact factor: 5.923

Review 7.  Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption.

Authors:  Michelle Boone; Peter M T Deen
Journal:  Pflugers Arch       Date:  2008-04-23       Impact factor: 3.657

8.  Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2014-06-26       Impact factor: 2.388

Review 9.  Management of severe hyponatremia: infusion of hypertonic saline and desmopressin or infusion of vasopressin inhibitors?

Authors:  Antonios H Tzamaloukas; Joseph I Shapiro; Dominic S Raj; Glen H Murata; Robert H Glew; Deepak Malhotra
Journal:  Am J Med Sci       Date:  2014-11       Impact factor: 2.378

Review 10.  High Water Intake and Progression of Chronic Kidney Diseases.

Authors:  Hoon Young Choi; Hyeong Cheon Park; Sung Kyu Ha
Journal:  Electrolyte Blood Press       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.